Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, PD, Safety, and Immunogenicity of Post-change CMAB807 vs Prolia in Healthy Chinese Subjects
NCT06361355Phase 1Completed
- Sponsor
- Taizhou Mabtech Pharmaceutical
- Start
- Nov 2023
- Primary completion
- Jun 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CMAB807 in osteoporosis (2 arms), sponsored by Taizhou Mabtech Pharmaceutical. Primary endpoints: Area Under the Plasma Concentration-time Curve From Zero Hours Extrapolated to Infinite Time up to 3000 hours and Maximum Concentration of Denosumab up to 3000 hours. Started Nov 2023; status: completed.
02
Drugs
CMAB807
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT06361355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06361355.